Independent Radiopharmacy Unit, Faculty of Pharmacy, Medical University of Lublin, Lublin, PL, 20093, Poland.
Independent Radiopharmacy Unit, Faculty of Pharmacy, Medical University of Lublin, Lublin, PL-20093, Poland.
Curr Med Chem. 2024;31(15):2003-2020. doi: 10.2174/0109298673258495231011065225.
Malignant melanoma is the rarest but most aggressive and deadly skin cancer. Melanoma is the result of a malignant transformation of melanocytes, which leads to their uncontrolled proliferation. Mutations in the mitogen-activated protein kinase (MAPK) pathway, which are crucial for the control of cellular processes, such as apoptosis, division, growth, differentiation, and migration, are one of its most common causes. BRAF kinase, as one of the known targets of this pathway, has been known for many years as a prominent molecular target in melanoma therapy, and the following mini-review outlines the state-of-the-art knowledge regarding its structure, mutations and mechanisms.
恶性黑素瘤是最罕见但最具侵袭性和致命性的皮肤癌。黑素瘤是黑素细胞恶性转化的结果，导致其不受控制地增殖。丝裂原活化蛋白激酶（MAPK）途径中的突变是细胞过程（如细胞凋亡、分裂、生长、分化和迁移）控制的关键，这是其最常见的原因之一。BRAF 激酶作为该途径的已知靶点之一，多年来一直是黑色素瘤治疗中的一个重要分子靶点，以下简要综述概述了其结构、突变和机制的最新知识。
